Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.
Chilelli MG, Signorelli C, Giron Berrios JR, Onorato A, Nelli F, Fabbri MA, Primi F, Marrucci E, Virtuoso A, Schirripa M, Mazzotta M, Ruggeri EM. Chilelli MG, et al. Among authors: nelli f. Cancer Diagn Progn. 2022 Jan 3;2(1):55-63. doi: 10.21873/cdp.10076. eCollection 2022 Jan-Feb. Cancer Diagn Progn. 2022. PMID: 35400002 Free PMC article.
Rhabdomyolysis from erlotinib: a case report.
Moscetti L, Nelli F, Ruggeri EM. Moscetti L, et al. Among authors: nelli f. Tumori. 2011 May-Jun;97(3):415-6. doi: 10.1177/030089161109700327. Tumori. 2011. PMID: 21789026 No abstract available.
Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.
Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I, Franco D, Ruggeri EM. Moscetti L, et al. Among authors: nelli f. Invest New Drugs. 2013 Aug;31(4):1035-43. doi: 10.1007/s10637-013-9936-9. Epub 2013 Feb 17. Invest New Drugs. 2013. PMID: 23417697
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Garassino MC, et al. Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22. Lancet Oncol. 2013. PMID: 23883922 Clinical Trial.
76 results